International Observational Study to Identify Subgroups of Patients With Autism Spectrum Disorder Ages 12 to 65

What this Trial Is About

Researchers are conducting an international, multicenter observational study to better understand subpopulations of patients with Autism Spectrum Disorder ASD. The study aims to identify sufficient biological and clinical markers that can help distinguish groups of patients who may respond best to specific medications. This research is sponsored by Stalicla SA and focuses on participants aged 12 to 65 years with a prior ASD diagnosis. This study does not involve any specific treatment but collects detailed clinical and molecular data from participants. Participants provide information through their health records and input from parents or reliable caregivers. The study characterizes ASD subpopulations based on clinical and molecular markers gathered at the start of the study. Participants will be involved in providing health history and molecular data on day 0 of the study. Researchers will analyze this information to define ASD subgroups. There are no interventional treatments, and safety monitoring involves excluding participants with recent fever or medical conditions that might interfere with study completion. The study runs until May 2027, allowing comprehensive data collection and analysis over time.

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder